Eli Lilly struck two strategic deals to expand its genetic‑medicine footprint: a partnership with SanegeneBio worth up to $1.2 billion in milestones to discover tissue‑targeted RNAi therapeutics using Sanegene’s LEAD delivery platform, and a separate agreement to acquire rights to an ultra‑rare pediatric eye‑disease gene therapy from MeiraGTx. The Sanegene pact includes upfront and equity investments and development/ commercialization carryovers. Lilly said the Sanegene collaboration supports its metabolic and cardiometabolic RNA pipeline ambitions and could enable infrequent subcutaneous dosing. The MeiraGTx deal adds an intraocular AAV program addressing an ultra‑rare form of childhood blindness. These transactions reinforce Lilly’s multi‑modal approach to metabolic and genetic diseases — combining RNAi, gene therapy and traditional small molecules — and reflect Big Pharma’s continued appetite for delivery and tissue‑targeting technologies.